We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The sentencing to death of Zheng Xiaoyu — the former head of China's State Food and Drug Administration, found guilty of accepting bribes — will do nothing to inspire confidence that China is building an effective drug regulatory process, says this Nature editorial.

It is more likely to confirm a patchy rule of law and highlight the slim chance of doing business fairly in such an environment.

According to the editorial, China rightly sees the establishment of an internationally competitive pharmaceutical industry as essential to public health and the nurturing of innovation in the life sciences. It is also important to scientific and economic development.

But for global drug companies, the risks of investing in this industry in China are considerable, and the benefits will only be seen if a dependable regulatory regime can be established.

To do this, says the editorial, China must take steps toward a transparent drug-review process which functions under open, public scrutiny.

Link to full article in Nature

Related topics